首页|新型抗凝药Ⅺ因子抑制剂监测方法及逆转策略研究进展

新型抗凝药Ⅺ因子抑制剂监测方法及逆转策略研究进展

扫码查看
Ⅺ因子(F Ⅺ)在血栓形成中扮演关键角色,而在止血过程中的作用较为有限。这种作用差异为预防和治疗血栓性疾病开辟了新的途径,即靶向F Ⅺ可能是一种更为安全的抗凝策略。目前,越来越多的F Ⅺ抑制剂进入Ⅲ期临床试验,尽管这些抑制剂展现出巨大的临床潜力,但其监测和逆转策略尚未明确,这给实验室监测和临床实践带来了新的挑战。本文在F Ⅺ的生理功能和F Ⅺ抑制剂在研药物的基础上,系统地探讨了F Ⅺ抑制剂的实验室检测抗凝活性证据,结合遗传性Ⅺ因子缺乏患者的治疗方案总结了F Ⅺ抑制剂的逆转方法,为制订临床治疗方案及逆转策略提供一定的参考。
Advances in Monitoring and Reversal Strategies for the Novel Anticoagulants Factor Ⅺ Inhibitors
Factor Ⅺ(F Ⅺ) plays a major role in thrombus amplification and an ancillary role in hemostasis. This differential contribution is expected to provide new ideas for the prevention and treatment of thrombotic diseases by targeting F Ⅺ as a potentially safer anticoagulation strategy. Currently,an increasing number of F Ⅺ inhibitors are entering phase Ⅲ clinical trials,and although these inhibitors showed promising clinical potential,the strategies for monitoring and reversing the effects of these inhibitors remain unclear,which poses new challenges for laboratory monitoring and clinical practice. This review,based on the physiological function of F Ⅺ and F Ⅺ inhibitors under study,systematically explored the laboratory evidence of coagulation activity linked to these inhibitors,summarized potential methods of reversal in combination with the treatment protocols of inherited F Ⅺ deficiency,which provided certain references for the development of clinical treatment protocols and reversal strategies.

AnticoagulantsFactor ⅪThrombosisAnticoagulantsDrug monitoringReversal

陈越秀、姚媛媛、孙大伟、王颖、吴超敏、赵麟茜、唐志峰、张冯江

展开 >

310009浙江省杭州市,浙江大学医学院附属第二医院麻醉科

310030浙江省杭州市,浙江大学生物医学工程与仪器科学学院

抗凝药 因子Ⅺ 血栓性疾病 抗凝治疗 药物监测 逆转

2025

中国全科医学
中国医院协会

中国全科医学

北大核心
影响因子:2.04
ISSN:1007-9572
年,卷(期):2025.28(3)